Eli Lilly and Company v. TWi Pharmaceuticals, Inc.
1:17-cv-00174
Overview
Parties
Defendant
TWi Pharmaceuticals USA, Inc. Operating Company
Represented By
0 Attorneys ListedTWi Pharmaceuticals, Inc. Operating Company
Represented By
0 Attorneys ListedPlaintiff
Acrux DDS Pty Ltd. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Eli Lilly Export S.A. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Eli Lilly and Company Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Eli Lilly and Company v. Amneal Pharmaceuticals LLC
ELI LILLY AND COMPANY v. PERRIGO COMPANY
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8435944
Method and composition for transdermal drug delivery
|
Filed: 2006-06-02
Issued: 2013-05-07
|
Active (0.9 yrs remaining)
+482d PTA
Expires: 2027-09-27
|
|
|
US8993520
Method and composition for transdermal drug delivery
|
Filed: 2010-06-25
Issued: 2015-03-31
|
Active (3.6 yrs remaining)
Expires: 2030-06-25
|
|
|
US9180194
Method and composition for transdermal drug delivery
|
Filed: 2014-10-08
Issued: 2015-11-10
|
Active (7.9 yrs remaining)
Expires: 2034-10-08
|
|
|
US8419307
Spreading implement
|
Filed: 2012-05-04
Issued: 2013-04-16
|
Active (5.5 yrs remaining)
Expires: 2032-05-04
|
|
|
US8177449
Spreading implement
|
Filed: 2007-02-26
Issued: 2012-05-15
|
Active (4.1 yrs remaining)
+1386d PTA
Expires: 2030-12-13
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+482 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).